Neil Fleshner
Chief Tech/Sci/R&D Officer at POINT Biopharma, Inc. (United States)
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Joe McCann | M | 47 |
POINT Biopharma, Inc. (United States)
 POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.
POINT Biopharma Corp.
 POINT Biopharma Corp. Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma Corp. is a Canadian company that develops next-generation radiopharmaceuticals for the treatment of cancer. The company is based in Toronto, Canada. POINT Biopharma develops radioligands, which are microscopic, cancer-seeking missiles used to diagnose and treat cancers such as non-Hodgkin's lymphoma and neuroendocrine tumors (NETs). To learn more about the company, interested parties can register online at https\://hub.pointbiopharma.com/investor-day-june-2023. The company was founded by Joe McCann. Joe McCann has been the CEO since incorporation. | 5 years |
| Allan Silber | M | 75 |
Verity Pharmaceuticals, Inc.
 Verity Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Verity Pharmaceuticals, Inc. operates as a pharmaceutical company. It provides therapeutically relevant agents to the Canadian healthcare community. The company was founded in 2016 and is headquartered in Mississauga, ON.
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.
POINT Biopharma Corp.
POINT Biopharma Corp. Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma Corp. is a Canadian company that develops next-generation radiopharmaceuticals for the treatment of cancer. The company is based in Toronto, Canada. POINT Biopharma develops radioligands, which are microscopic, cancer-seeking missiles used to diagnose and treat cancers such as non-Hodgkin's lymphoma and neuroendocrine tumors (NETs). To learn more about the company, interested parties can register online at https\://hub.pointbiopharma.com/investor-day-june-2023. The company was founded by Joe McCann. Joe McCann has been the CEO since incorporation. | 6 years |
| Jonathan Goodman | M | 56 |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.
POINT Biopharma Corp.
POINT Biopharma Corp. Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma Corp. is a Canadian company that develops next-generation radiopharmaceuticals for the treatment of cancer. The company is based in Toronto, Canada. POINT Biopharma develops radioligands, which are microscopic, cancer-seeking missiles used to diagnose and treat cancers such as non-Hodgkin's lymphoma and neuroendocrine tumors (NETs). To learn more about the company, interested parties can register online at https\://hub.pointbiopharma.com/investor-day-june-2023. The company was founded by Joe McCann. Joe McCann has been the CEO since incorporation. | 4 years |
| Ari Shomair | M | - |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | - |
| Howard M. Glase | M | - |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million.
Verity Pharmaceuticals, Inc.
Verity Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Verity Pharmaceuticals, Inc. operates as a pharmaceutical company. It provides therapeutically relevant agents to the Canadian healthcare community. The company was founded in 2016 and is headquartered in Mississauga, ON.
POINT Biopharma Corp.
POINT Biopharma Corp. Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma Corp. is a Canadian company that develops next-generation radiopharmaceuticals for the treatment of cancer. The company is based in Toronto, Canada. POINT Biopharma develops radioligands, which are microscopic, cancer-seeking missiles used to diagnose and treat cancers such as non-Hodgkin's lymphoma and neuroendocrine tumors (NETs). To learn more about the company, interested parties can register online at https\://hub.pointbiopharma.com/investor-day-june-2023. The company was founded by Joe McCann. Joe McCann has been the CEO since incorporation. | 8 years |
| Margaret Gilmour | F | 64 |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | 4 years |
| William Demers | M | 66 |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | 4 years |
| Gerald Hogue | M | 66 |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | 4 years |
| Justyna Kelly | F | 39 |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | 3 years |
| Michael Thompson | M | - | 1 years | |
| Philip Johnson | M | 59 | 1 years | |
| Tino Alavie | M | - |
University of Toronto
| - |
| Jessica Jensen | F | 44 |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | 4 years |
| Maryann Feldman | M | - |
University of Toronto
| - |
| Peggy Gilmour | F | - |
POINT Biopharma Corp.
POINT Biopharma Corp. Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma Corp. is a Canadian company that develops next-generation radiopharmaceuticals for the treatment of cancer. The company is based in Toronto, Canada. POINT Biopharma develops radioligands, which are microscopic, cancer-seeking missiles used to diagnose and treat cancers such as non-Hodgkin's lymphoma and neuroendocrine tumors (NETs). To learn more about the company, interested parties can register online at https\://hub.pointbiopharma.com/investor-day-june-2023. The company was founded by Joe McCann. Joe McCann has been the CEO since incorporation.
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | 4 years |
| Gerry Hogue | M | - |
POINT Biopharma Corp.
POINT Biopharma Corp. Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma Corp. is a Canadian company that develops next-generation radiopharmaceuticals for the treatment of cancer. The company is based in Toronto, Canada. POINT Biopharma develops radioligands, which are microscopic, cancer-seeking missiles used to diagnose and treat cancers such as non-Hodgkin's lymphoma and neuroendocrine tumors (NETs). To learn more about the company, interested parties can register online at https\://hub.pointbiopharma.com/investor-day-june-2023. The company was founded by Joe McCann. Joe McCann has been the CEO since incorporation.
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | 4 years |
| Jay Silber | M | - |
Verity Pharmaceuticals, Inc.
Verity Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Verity Pharmaceuticals, Inc. operates as a pharmaceutical company. It provides therapeutically relevant agents to the Canadian healthcare community. The company was founded in 2016 and is headquartered in Mississauga, ON. | 5 years |
| Kieran Murphy | M | - |
University of Toronto
| - |
| Michael Gottlieb | M | 45 |
POINT Biopharma, Inc. (United States)
POINT Biopharma, Inc. (United States) Miscellaneous Commercial ServicesCommercial Services Part of POINT Biopharma Global, Inc., POINT Biopharma, Inc. (United States) develops next-generation radioligand therapies for the treatment of cancer. The company is based in Indianapolis, IN. Joe McCann has been the CEO of the company since 2019. POINT Biopharma, Inc. (United States was acquired by Therapeutics Acquisition Corp. on June 30, 2021 for $578.95 million. | 4 years |
| J. Prichard | M | 75 |
University of Toronto
| 40 years |
| David Newman | M | - |
University of Toronto
| - |
| Sebastian Jaimungal | M | - |
University of Toronto
| 14 years |
| Zabeen Hirji | F | 63 |
University of Toronto
| - |
| Andres M. Lozano | M | - |
University of Toronto
| - |
| Richard Ernest Gilbert | M | - |
University of Toronto
| - |
| Fabio Varlese | M | - |
University of Toronto
| - |
| Mauro di Pasquale | M | - |
University of Toronto
| - |
| Araba Chintoh | M | - |
University of Toronto
| - |
| Joshua Rosenblat | M | - |
University of Toronto
| - |
| Thomas Hudson | M | 62 |
University of Toronto
| 17 years |
| Mary Gospodarowicz | M | 75 |
University of Toronto
| - |
| Radu Vestemean | M | - |
University of Toronto
| - |
| John G. Flanagan | M | 65 |
University of Toronto
| - |
| Hai Peng Xie | M | 54 |
University of Toronto
| 9 years |
| Anita Anand | F | - |
University of Toronto
| 18 years |
| Roger McIntyre | M | - |
University of Toronto
| 12 years |
| I. Anita Anand | F | - |
University of Toronto
| 18 years |
| Andong Huang | M | 27 |
University of Toronto
| - |
| Avrum Gotlieb | M | - |
University of Toronto
| - |
| Harvey Botting | M | - |
University of Toronto
| - |
| Andrea Luva Moser | M | - |
University of Toronto
| - |
| Shari Fell | F | - |
University of Toronto
| - |
| S. Empey | M | - |
University of Toronto
| - |
| Phillip A. Bauman | M | 67 |
The Trustees of Columbia University in The City of New York
| 27 years |
| Rulan S. Parekh | M | - |
University of Toronto
| - |
| Brian Lawson | M | 64 |
University of Toronto
| - |
| Thomas Enright | M | - |
University of Toronto
| - |
| Mark S. Fox | M | - |
University of Toronto
| - |
| Tony Naldrett | M | - |
University of Toronto
| 26 years |
| David A. Asper | M | 64 |
University of Toronto
| - |
| Robert Hubbard | M | 66 |
The Trustees of Columbia University in The City of New York
| 27 years |
| Kent Moore | M | - |
University of Toronto
| - |
| Melinda Rogers-Hixon | F | 53 |
University of Toronto
| - |
| Brian H. Barber | M | - |
University of Toronto
| - |
| Frederick H. Lowy | M | - |
University of Toronto
| - |
| Sabin C. Streeter | M | 82 |
The Trustees of Columbia University in The City of New York
| 27 years |
| Roger L. Martin | M | 67 |
University of Toronto
| - |
| Ellen Oran Kaden | F | 72 |
The Trustees of Columbia University in The City of New York
| 28 years |
| Wendy K. Dobson | M | 82 |
University of Toronto
| 31 years |
| William Davis | M | 94 |
University of Toronto
| - |
| Eugene Lucas Fiume | M | 66 |
University of Toronto
| 29 years |
| Vigen Nazarian | M | - |
University of Toronto
| - |
| Peter Mills | M | - |
University of Toronto
| - |
| Rajiv Chopra | M | - |
University of Toronto
| - |
| Paul J. Santerre | M | - |
University of Toronto
| - |
| Andrew Avi Goldenberg | M | 80 |
University of Toronto
| 42 years |
| Richard E. Venn | M | 72 |
University of Toronto
| - |
| Gabriele M. T. DEleuterio | M | - |
University of Toronto
| - |
| Paul Halpern | M | - |
University of Toronto
| - |
| Paul Chipperton | M | - |
University of Toronto
| - |
| Robert Casper | M | - |
University of Toronto
| - |
| Molly Shoichet | M | - |
University of Toronto
| 10 years |
| Rebecca Adams | F | - |
University of Toronto
| - |
| Don Duval | M | - |
University of Toronto
| - |
| Anatoly Langer | M | - |
University of Toronto
| - |
| Sandra Hanington | F | 62 |
University of Toronto
| 4 years |
| Elizabeth J. Keefer | F | - |
The Trustees of Columbia University in The City of New York
| 27 years |
| Judith Goldring | F | 59 |
University of Toronto
| - |
| Mary Cardosa | M | - |
University of Toronto
| - |
| Paulette L. Kennedy | F | - |
University of Toronto
| - |
| James Appleyard | M | - |
University of Toronto
| - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Valdis Martinsons | M | - |
University of Toronto
| 7 years |
| Stuart R. Nayman | M | - |
University of Toronto
| 7 years |
| Hank L. Torbert | M | 52 |
The Trustees of Columbia University in The City of New York
| 3 years |
| Brian Miron | M | - |
University of Toronto
| 5 years |
| James Stone | M | - |
The Trustees of Columbia University in The City of New York
| 10 years |
| Ming Yeung Lau | M | 45 |
The Trustees of Columbia University in The City of New York
| 5 years |
| David Carter | M | - |
The Trustees of Columbia University in The City of New York
| 3 years |
| David Ham | M | - |
The Trustees of Columbia University in The City of New York
| 5 years |
| Andrew Woo | M | - |
University of Toronto
| 6 years |
| Saurin Dinesh Shah | M | 57 |
The Trustees of Columbia University in The City of New York
| 3 years |
| Andrew Pyle | M | - |
University of Toronto
| 5 years |
| Steven Gutterman | M | 55 |
The Trustees of Columbia University in The City of New York
| 5 years |
| Yi Ping Wang | M | - |
The Trustees of Columbia University in The City of New York
| 5 years |
| Ari H. Shrage | M | - |
The Trustees of Columbia University in The City of New York
| 6 years |
| Anil Patel | M | - |
The Trustees of Columbia University in The City of New York
| 4 years |
| Sherri Scribner | F | - |
The Trustees of Columbia University in The City of New York
| 6 years |
| Ehud A. Gelblum | M | - |
The Trustees of Columbia University in The City of New York
| 5 years |
| Alicia Damley | F | - |
University of Toronto
| 7 years |
| Henry Lu | M | 58 |
The Trustees of Columbia University in The City of New York
| 6 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| Canada | 73 | 73.00% |
| United States | 33 | 33.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Neil Fleshner
- Personal Network
